Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
Lucia Graziani, Leonardo Gori, Tommaso Manciulli, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 78, Iss. 2, pp. 555-558
Open Access | Times Cited: 18

Showing 18 citing articles:

Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicine
Ling Ye, Shicheng Fan, Pengfei Zhao, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 9, pp. 3598-3637
Open Access | Times Cited: 29
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection
Zeno Pasquini, Alice Toschi, Beatrice Casadei, et al.
Hematological Oncology (2023) Vol. 41, Iss. 5, pp. 904-911
Open Access | Times Cited: 26
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
Sammy Huygens, Arvind Gharbharan, Yasmina Serroukh, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1644-1648
Open Access | Times Cited: 14
Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients
Massimiliano Lanzafame, Martina Gottardi, L Guella, et al.
Journal of Chemotherapy (2023) Vol. 35, Iss. 7, pp. 623-626
Closed Access | Times Cited: 11
Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium
Sara Tomassetti, Luca Ciani, Valentina Luzzi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer
Catherine Liu, Leah H Yoke, Pooja Bhattacharyya, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 10
Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID‐19 infection at an ambulatory cancer center
Eduardo Sanchez, Elizabeth M. Krantz, Leah M. Yoke, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 3
Antiviral therapies for the management of persistent coronavirus disease 2019 in immunocompromised hosts: A narrative review
Paul Kinsella, Michael A. Moso, C. Orla Morrissey, et al.
Transplant Infectious Disease (2024) Vol. 26, Iss. 3
Open Access | Times Cited: 3
Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir/ritonavir courses: a case report
Anna Lindahl, Maarit J. Ahava, Mia Haukipää, et al.
Infectious Diseases (2023) Vol. 55, Iss. 8, pp. 585-589
Closed Access | Times Cited: 9
Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, et al.
Infectious Disease Reports (2023) Vol. 15, Iss. 6, pp. 662-678
Open Access | Times Cited: 7
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2
Kabita Pandey, Arpan Acharya, Dhananjaya Pal, et al.
Antiviral Research (2024) Vol. 227, pp. 105904-105904
Closed Access | Times Cited: 2
Triple antiviral treatment for COVID-19 in an immunocompromised patient
Chiara Dentone, Małgorzata Mikulska, Chiara Sepulcri, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 8, pp. 2097-2099
Closed Access | Times Cited: 6
Treatment of Persistent Coronavirus Disease 2019 (COVID-19) in a B Cell Acute Lymphoblastic Leukemia Patient with Using Nirmatrelvir/Ritonavir Extended Course: A Case Report
Hassan Almarhabi, Aisha Alharbi, Mai Alalawi, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 10, pp. 102526-102526
Open Access | Times Cited: 1
Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma
Seowoong Jung, Yu Yagi, Kazuaki Fukushima, et al.
IDCases (2023) Vol. 34, pp. e01890-e01890
Open Access | Times Cited: 2
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments
Flavia Sanmartin, Eugenia Magrini, Emanuele Rando, et al.
American Journal of Case Reports (2024) Vol. 25
Open Access
Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient
Catia Cillóniz, Antoni Torres
Clinics in Chest Medicine (2024) Vol. 46, Iss. 1, pp. 203-216
Closed Access
Antiviral treatment or mAbs for persistent SARS‐COV‐2 infection in patients with hematologic malignancies: A case series
Ignacio Pérez Catalán, Iris Gómez‐Alfaro, Sergio García‐Muñoz, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access
Page 1

Scroll to top